Form 4: Evolent Health General Counsel Jonathan Weinberg Granted Over 23,000 Restricted Stock Units

Evolent Health, Inc. General Counsel Jonathan Weinberg was granted 23,394 Class A Common Stock restricted stock units as part of the company's annual incentive compensation plan.

Summary

• Jonathan Weinberg, General Counsel of Evolent Health, Inc. (EVH), was granted 23,394 restricted stock units (RSUs) of Class A Common Stock.
• The transaction date for this grant was July 1, 2025.
• These RSUs were granted at a price of $0 per unit, which is typical for compensation awards.
• Following this transaction, Mr. Weinberg beneficially owns 254,179 shares, which includes previously reported restricted stock units.
• The RSUs will vest in three tranches: 34% on July 1, 2026, 33% on July 1, 2027, and 33% on July 1, 2028.
• This grant is part of the annual award cycle approved by the Compensation Committee of the Company's Board of Directors.
• This specific portion of the award was contingent upon shareholder approval of the issuance of additional shares under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, which occurred on June 5, 2025, at the Company's Annual Meeting.

Sentiment

Score: 6

Explanation: The document reports a routine executive compensation grant, which is a positive for aligning management interests with shareholders, but does not contain information that would significantly alter the company's financial outlook or strategic direction.

Positives

• The grant of restricted stock units to General Counsel Jonathan Weinberg aligns his interests with those of shareholders, as the value of the award is tied to the company's stock performance.
• The award is part of a structured annual incentive compensation plan, indicating a consistent approach to executive remuneration.
• Shareholder approval for the underlying incentive plan demonstrates good corporate governance and transparency.

Future Outlook

The document indicates future vesting dates for the granted restricted stock units on July 1, 2026, July 1, 2027, and July 1, 2028, tying a portion of the General Counsel's compensation to future company performance.

Management Comments

• The award was "approved by the Compensation Committee of the Company's Board of Directors as part of the annual award cycle."

Industry Context

The grant of restricted stock units is a common form of executive compensation in publicly traded companies, particularly in the technology and healthcare sectors, designed to align executive incentives with long-term shareholder value creation.

Comparison to Industry Standards

• Granting restricted stock units as part of an annual compensation cycle is a standard practice across various industries, including healthcare technology, to incentivize key executives.
• The vesting schedule over multiple years is also typical for long-term incentive plans, ensuring retention and sustained performance alignment.
• Specific comparable companies or projects are not detailed in this filing, as it focuses solely on an individual's compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the General Counsel's long-term interests with shareholder value creation, as the value of the award is tied to the company's stock performance.
• Employees: This grant is part of a broader incentive compensation plan, which can contribute to a positive compensation structure for key personnel.

Next Steps

• Vesting of 34% of the granted restricted stock units on July 1, 2026.
• Vesting of 33% of the granted restricted stock units on July 1, 2027.
• Vesting of 33% of the granted restricted stock units on July 1, 2028.

Key Dates

Recommendation

Keywords

Evolent Health, EVH, Form 4, Restricted Stock Units, RSU, insider transaction, executive compensation, Jonathan Weinberg, General Counsel, equity grant, incentive plan